Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 166-173

  Schellenberger, Mario T ^a   Farinelle, Sophie ^a   Willième, Stéphanie ^a   Muller, Claude P ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Adjuvant; Benzo a pyrene; Hapten specific antibodies; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BENZO[A]PYRENE; FREUND ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MIFAMURTIDE; MONTANIDE ISA 51; QUIL A; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BIOLOGICAL ACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOREACTIVITY; METABOLITE; MOUSE; NONHUMAN; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES; BENZO(A)PYRENE; CANCER VACCINES; CARCINOGENS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; POLYSORBATES; SAPONINS; SQUALENE; VACCINES, CONJUGATE;

EID: 84855730847     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14579     Document Type: Article

References (58)

1. Hattemer-Frey HA, Travis CC. Benzo-a-pyrene: environmental partitioning and human exposure. Toxicol Ind Health 1991; 7:141-57.
2. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91:1194-210. (Pubitemid 29357186)
3. Phillips DH. Polycyclic aromatic hydrocarbons in the diet. Mutat Res 1999; 443:139-47. (Pubitemid 29327272)
4. Lambré C, Muller C. Collection of occurrence data on polycyclic aromatic hydrocabons in food. Directorate- General Health and Consumer Protection 2004.
5. Thyssen J, Althoff J, Kimmerle G, Mohr U. Inhalation studies with benzo[a]pyrene in Syrian golden hamsters. J Natl Cancer Inst 1981; 66:575-7. (Pubitemid 11098561)
6. Wolterbeek AP, Schoevers EJ, Rutten AA, Feron VJ. A critical appraisal of intratracheal instillation of benzo[a] pyrene to Syrian golden hamsters as a model in respiratory tract carcinogenesis. Cancer Lett 1995; 89:107-16.
7. Harris CC, Vahakangas K, Newman MJ, Trivers GE, Shamsuddin A, Sinopoli N, et al. Detection of benzo[a] pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc Natl Acad Sci USA 1985; 82:6672-6. (Pubitemid 16228882)
8. Haugen A, Becher G, Benestad C, Vahakangas K, Trivers GE, Newman MJ, et al. Determination of polycyclic aromatic hydrocarbons in the urine, benzo(a) pyrene diol epoxide-DNA adducts in lymphocyte DNA and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Research 1986; 46:4178-83. (Pubitemid 16075927)
9. Newman MJ, Light BA, Weston A, Tollurud D, Clark JL, Mann DL, et al. Detection and characterization of human serum antibodies to polycyclic aromatic hydrocarbon diol-epoxide DNA adducts. The Journal Of Clinical Investigation 1988; 82:145-53. (Pubitemid 18262510)
10. Lee BM, Strickland PT. Antibodies to carcinogen- DNA adducts in mice chronically exposed to polycyclic aromatic hydrocarbons. Immunology Letters 1993; 36:117-23. (Pubitemid 23175184)
11. Galati R, Zijno A, Crebelli R, Falasca G, Tomei F, Iecher F, et al. Detection of antibodies to the benzo(a) pyrene diol epoxide-DNA adducts in sera from individuals exposed to low doses of polycyclic aromatic hydrocarbons. J Exp Clin Cancer Res 2001; 20:359-64. (Pubitemid 32980037)
12. De Buck SS, Muller CP. Immunopropylactic approaches against chemical carcinogenesis. Vaccine 2005; 23:2403-6. (Pubitemid 40341492)
13. Glushkov AN. Immunological mechanisms of adaptation to the low-weight chemical compounds in ontogenesis. Med Hypotheses 2003; 61:405-11. (Pubitemid 37100477)
14. Oliver JL, Pashmi G, Barnett P, Mettens P, Biemans R, Monteyne P, et al. Development of an anti-cotinine vaccine to potentiate nicotine-based smoking cessation strategies. Vaccine 2007; 25:7354-62. (Pubitemid 47484018)
15. Silbart LK, Rasmussen MV, Oliver AR. Immunoprophylactic intervention in chemical toxicity and carcinogenicity. Vet Hum Toxicol 1997; 39:37-43. (Pubitemid 27045236)
16. Bismuth C, Borron SW, Baud FJ, Taboulet P, Scherrmann JM. Immunotoxicotherapy: successes, disappointments and hopes. Hum Exp Toxicol 1997; 16:602-8. (Pubitemid 27480882)
17. Butler VP Jr. Antibodies as specific antagonists of toxins, drugs and hormones. Pharmacol Rev 1982; 34:109-14.
18. Butler VP Jr, Beiser SM. Antibodies to small molecules: biological and clinical applications. Adv Immunol 1973; 17:255-310.
19. Colburn WA. Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/ toxicologic effects of drugs. Drug Metab Rev 1980; 11:223-62. (Pubitemid 11140161)
20. Scherrmann JM, Terrien N, Urtizberea M, Pierson P, Denis H, Bourre JM. Immunotoxicotherapy: present status and future trends. J Toxicol Clin Toxicol 1989; 27:1-35. (Pubitemid 19211424)
21. Sullivan JB Jr. Immunotherapy in the poisoned patient. Overview of present applications and future trends. Med Toxicol 1986; 1:47-60.
22. de Villiers SH, Lindblom N, Kalayanov G, Gordon S, Baraznenok I, Malmerfelt A, et al. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine 28:2161-8.
23. De Buck SS, Augustijns P, Muller CP. Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J Pharmacol Exp Ther 2005; 313:640-6. (Pubitemid 40604164)
24. De Buck SS, Bouche FB, Brandenburger A, Muller CP. Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis? Carcinogenesis 2005; 26:835-44. (Pubitemid 41214347)
25. De Buck SS, Schellenberger MT, Ensch C, Muller CP. Effects of antibodies induced by a conjugate vaccine, on 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone absorptive transport, metabolism and proliferation of human lung cells. Int J Cancer 2009.
26. Grova N, Prodhomme EJ, Schellenberger MT, Farinelle S, Muller CP. Modulation of carcinogen bioavailability by immunisation with benzo[a]pyrene-conjugate vaccines. Vaccine 2009; 27:4142-51.
27. Silbart LK, Keren DF. Reduction of intestinal carcinogen absorption by carcinogen-specific secretory immunity. Science 1989; 243:1462-4. (Pubitemid 19087127)
28. Rasmussen MV, Barker TT, Silbart LK. High affinity binding site-mediated prevention of chemical absorption across the gastrointestinal tract. Toxicology Letters 2001; 125:51-9. (Pubitemid 33043754)
29. Schellenberger MT, Grova N, Willieme S, Farinelle S, Prodhomme EJ, Muller CP. Modulation of Benzo[a] pyrene induced immunotoxicity in mice actively immunized with a B[a]P-diphtheria toxoid conjugate. Toxicol Appl Pharmacol 2009.
30. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008; 3:2547.
31. Wagena EJ, de Vos A, Horwith G, van Schayck CP. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res 2008; 10:213-8.
32. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005; 78:456-67. (Pubitemid 41698900)
33. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy and Phase I safety and immunogenicity. Eur J Immunol 2005; 35:2031-40. (Pubitemid 41015042)
34. Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 2006; 24:1680-6. (Pubitemid 43238245)
35. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197-203.
36. Nitayaphan S, Khamboonruang C, Sirisophana N, Morgan P, Chiu J, Duliege AM, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine 2000; 18:1448-55.
37. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26:3209-22.
38. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12:1-99.
39. Lightowlers MW. Cestode vaccines: origins, current status and future prospects. Parasitology 2006; 133:27-42.
40. Lightowlers MW, Waterkeyn JG, Rothel JS, Gauci CG, Harrison GB. Host-protective fragments and antibody binding epitopes of the Taenia ovis 45W recombinant antigen. Parasite Immunol 1996; 18:507-13. (Pubitemid 26342889)
41. Ebbesen P, Dalsgaard K, Madsen M. Prolonged survival of AKR mice treated with the saponin adjuvant Quil A. Acta Pathol Microbiol Scand A 1976; 84:358-60.
42. Dalsgaard K. Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch Gesamte Virusforsch 1974; 44:243-54.
43. Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 1996; 13:1-55. (Pubitemid 26300177)
44. Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 2009; 27:1787-96.
45. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82:488-96. (Pubitemid 39421058)
46. Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor, NY (USA): Cold Spring Harbor Laboratory 1988.
47. Junghans RP. IgG biosynthesis: no "immunoregulatory feedback". Blood 1997; 90:3815-8.
48. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000; 22:809-19. (Pubitemid 30616407)
49. Hieda Y, Keyler DE, VanDeVoort JT, Niedbala RS, Raphael DE, Ross CA, et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl) 1999; 143:150-7. (Pubitemid 29187639)
50. Janoff EN, Hardy WD, Smith PD, Wahl SM. Humoral recall responses in HIV infection. Levels, specificity and affinity of antigen-specific IgG. J Immunol 1991; 147:2130-5.
51. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65:191-8. (Pubitemid 30018012)
52. Lewtas J, Walsh D, Williams R, Dobias L. Air pollution exposure-DNA adduct dosimetry in humans and rodents: evidence for non-linearity at high doses. Mutat Res 1997; 378:51-63. (Pubitemid 27342084)
53. rd communication (author's transl)]. Zentralbl Bakteriol Orig B 1975; 161:85-103.
54. de Vries A, Dolle ME, Broekhof JL, Muller JJ, Kroese ED, van Kreijl CF, et al. Induction of DNA adducts and mutations in spleen, liver and lung of XPAdeficient/ lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development. Carcinogenesis 1997; 18:2327-32. (Pubitemid 28134645)
55. Moir D, Viau A, Chu I, Withey J, McMullen E. Pharmacokinetics of benzo[a]pyrene in the rat. J Toxicol Environ Health A 1998; 53:507-30.
56. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben- Efraim S, Gupta CK. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993; 11:293-306. (Pubitemid 23061171)
57. Grabarek Z, Gergely J. Zero-length crosslinking procedure with the use of active esters. Anal Biochem 1990; 185:131-5. (Pubitemid 20082102)
58. Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun 2005; 73:828-33. (Pubitemid 40165739)